IPN Share Price

Open 109.00 Change Price %
High 110.20 1 Day 1.15 1.05
Low 108.70 1 Week -2.60 -2.30
Close 110.20 1 Month 13.02 13.40
Volume 169030 1 Year 56.56 105.44
52 Week High 113.65
52 Week Low 50.76
IPN Important Levels
Resistance 2 111.59
Resistance 1 111.02
Pivot 109.70
Support 1 109.38
Support 2 108.81
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
AVQ 0.47 0.00%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
BRS 12.00 0.00%
More..
EPA France Top Gainers Stocks
MLGEO 0.03 50.00%
MLDIG 1.20 33.33%
RX 5.26 30.20%
RX 5.26 30.20%
RX 5.26 30.20%
ALALO 0.10 25.00%
DBG 6.33 21.97%
MLVER 8.00 18.52%
APAM 33.78 15.72%
APAM 33.78 15.72%
More..
EPA France Top Losers Stocks
OXI 0.06 -14.29%
OXI 0.06 -14.29%
MLAAE 4.50 -10.00%
ALDV 0.09 -10.00%
CIB 0.09 -10.00%
CIB 0.09 -10.00%
CIB 0.09 -10.00%
CIB 0.09 -10.00%
MLGES 2.30 -8.00%
ASY 35.05 -5.27%
More..

Ipsen (EPA: IPN)

IPN Technical Analysis 5
As on 23rd May 2017 IPN Share Price closed @ 110.20 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 72.02 & Strong Buy for SHORT-TERM with Stoploss of 97.95 we also expect STOCK to react on Following IMPORTANT LEVELS.
IPN Target for May
1st Target up-side 115.84
2nd Target up-side 122.15
3rd Target up-side 128.45
1st Target down-side 97.86
2nd Target down-side 91.55
3rd Target down-side 85.25
IPN Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.ipsen.com
IPN Address
IPN
65, quai Georges Gorse
Cedex
Boulogne-Billancourt, 92650
France
Phone: 33 1 58 33 50 00
Fax: 33 1 58 33 50 01
IPN Latest News
Interactive Technical Analysis Chart Ipsen ( IPN EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Ipsen
IPN Business Profile
Ipsen S.A. operates as a pharmaceutical company worldwide. It offers drugs in the areas of uro-oncology, endocrinology, neurology, gastroenterology, cardiovascular, and cognitive disorders. The company’s products include Decapeptyl, a peptide formulation for injection in the treatment of advanced prostate cancer; Hexvix that is used to enhance detection of bladder cancer; and Somatuline and Somatuline Autogel, which are used in the treatment of acromegaly and neuroendocrine tumours. Ipsen S.A. also offers NutropinAq, a liquid formulation used in the treatment of growth failure in children and growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum neurotoxin type A complex used to treat spasticity of upper limbs following a stroke, as well as the spasticity of other muscles. In addition, it provides Smecta, a natural clay-based drug used in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan that is used in the treatment of age-related cognitive disorders. Further, the company offers Nisis and Nisisco oral formulations containing valsartan used in the treatment of hypertension; and Adenuric for the treatment of gout. Additionally, it is developing products in the areas of neurology, endocrinology, and uro-oncology, including BN82451, Tasquinimod, Somatuline Autogel, Dysport, Dysport Next Generation, and Decapeptyl. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.